Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
11 pending office actions • 1 client • 11 examiners • 4 art units • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
BakerHostetler - Inovio covers the Biotechnology & Pharmaceuticals technology area. The firm's overall metrics include 29555 career applications and a resolved allowance rate pct of 83.16. For this specific relationship, there are 10 pending office actions. The 83.16 percent allowance rate provides a baseline for the likelihood of success for its client base. Practitioners can use this percentage to evaluate the firm's historical performance across its career filings.
The average of 3.51 office actions per allowance remains consistent with the firm's general prosecution profile. This 3.51 average helps in setting expectations for the number of interactions required to reach a final decision. With 29555 applications in its history, the firm has established a clear performance record. The 10 pending actions represent the current active workload for this specific account. This data provides a clear view of the prosecution landscape for Inovio within the firm's biotech practice.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (18%) |
| §103 only | 3 (27%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZAMORY, JUSTIN L | 1 | 72.9% | +17.4% |
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| HILL, MYRON G | 1 | 66.2% | +20.6% |
| GILL, RACHEL B | 1 | 65.6% | +28.3% |
| FARRAR, LAUREN PENG | 1 | 78.6% | +15.5% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
| HENZE, DAVID V | 1 | 69.7% | +23.3% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | GILL, RACHEL B | 34d |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | ALAM, DANYAL HASSAN | — |
| 18174298 | Handheld Electroporation Devices, And Related Systems And Methods | HENZE, DAVID V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | GILL, RACHEL B | 34d |
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | ZAMORY, JUSTIN L | — |
| 18593320 | METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | ALLEN, MICHAEL D | — |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | HILL, MYRON G | — |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | FARRAR, LAUREN PENG | — |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | KINSEY WHITE, NICOLE ERIN | — |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | PARKIN, JEFFREY S | — |
| 18174298 | Handheld Electroporation Devices, And Related Systems And Methods | HENZE, DAVID V | — |
| Client (Assignee) | Pending OAs |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | 11 |
| Art Unit | Apps |
|---|---|
| 1671 | 5 |
| 3783 | 2 |
| 1672 | 2 |
| 2859 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18648280 | KINETIC VACUUM TREATMENT DEVICES, SYSTEMS, AND METHODS | Inovio Pharmaceuticals, Inc. | ZAMORY, JUSTIN L | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18593320 | METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | Inovio Pharmaceuticals, Inc. | ALLEN, MICHAEL D | 1671 | §102§103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18493936 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | Inovio Pharmaceuticals, Inc. | HILL, MYRON G | 1671 | §101§103 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | Inovio Pharmaceuticals, Inc. | GILL, RACHEL B | 1671 | §102§103§112Other | Non-Final OA | 34d | Pending | Oct 24, 2023 |
| 18493512 | Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods | Inovio Pharmaceuticals Inc. | FARRAR, LAUREN PENG | 3783 | §103 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18486708 | Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same | Inovio Pharmaceuticals, Inc. | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112DP | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | Inovio Pharmaceuticals, Inc. | ALAM, DANYAL HASSAN | 1672 | §101§103 | Final Rejection | — | Pending | Apr 14, 2023 |
| 18300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | Inovio Pharmaceuticals, Inc. | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18174298 | Handheld Electroporation Devices, And Related Systems And Methods | Inovio Pharmaceuticals, Inc. | HENZE, DAVID V | 2859 | §102§103 | Non-Final OA | — | Pending | Feb 24, 2023 |
| 17221032 | COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA | Inovio Pharmaceuticals, Inc. | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | — | Pending | Apr 02, 2021 |
| 16804707 | VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD | Inovio Pharmaceuticals, Inc. | VU, QUYNH-NHU HOANG | 3783 | §103 | Final Rejection | 37d overdue | Pending | Feb 28, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial